-
May 23, 2013
Boehringer Ingelheim says it will act promptly to resolve a series of manufacturing complaints highlighted by regulators in the USA concerning violations at its German headquarters
Full story
-
March 27, 2013
The European Medicines Agency is following a move by its counterpart across the Atlantic and is investigating the possibility of an increased risk to the pancreas linked to use of new diabetes drugs
Full story
-
February 11, 2013
Shire has settled all litigation with Impax Laboratories concerning a dispute over a generic version of the attention-deficit hyperactivity disorder drug Adderall XR
Full story
-
January 10, 2013
Far too few NHS Trusts in England are providing easy access to information on clinical-research opportunities., a 'mystery shopper' investigation by the National Institute for Health Research Clinical Research Network has found.
Full story
-
June 22, 2012
Swiss drug giant Roche has found itself under the close scrutiny of European officials who are investigating its practices surrounding drug safety reporting.
Full story
-
January 18, 2012
Roche stands accused of withholding key trial data relating to its antiviral Tamiflu, raising questions about its safety and effectiveness
Full story
-
November 03, 2011
GlaxoSmithKline has reached a $3 billion agreement with the US government to settle investigations begun into the drug major's sales and marketing practices, most notably of the controversial diabetes drug Avandia
Full story
-
October 24, 2011
The European Commission has opened an antitrust investigation against Johnson & Johnson and Novartis that may have hindered the entry of generic versions of the former's pain killer fentanyl
Full story
-
July 07, 2011
The EC has closed an antitrust investigation of Boehringer Ingelheim which had been accused of effectively blocking market entry to competition to its COPD blockbuster Spiriva
Full story
-
June 13, 2011
Gilead Sciences has received a subpoena from the US Department of Justice related to "the manufacture, and related quality and distribution practices" of most of its products
Full story